Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 14/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.54 |
| ▸ | USP7 | Q93009 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17270330 | 0.86 | ACKR3 (0.72) | ACKR3CDK5CDK5R1RAB9A | |
| SCHEMBL17270169 | 0.84 | ACKR3 (0.74) | ACKR3CDK5CDK5R1GAAHTT | |
| SCHEMBL6402701 | 0.79 | F10 (0.49) | ACKR3MAPK1 | |
| SCHEMBL5781275 | 0.78 | F10 (0.70) | ACKR3CDK5CDK5R1 | |
| SCHEMBL6401507 | 0.77 | ACHE (0.50) | ACKR3MAPK1 | |
| SCHEMBL7600247 | 0.76 | KDM4E (0.69) | ACKR3CDK5CDK5R1GAA | |
| SCHEMBL27101124 | 0.76 | ACKR3 (0.60) | ACKR3USP7GAAHTTRAB9A | |
| SCHEMBL5254353 | 0.75 | ACKR3 (0.72) | ACKR3CDK5CDK5R1 | |
| SCHEMBL17270146 | 0.75 | ACKR3 (0.72) | ACKR3GAA | |
| SCHEMBL10515943 | 0.75 | CDK5 (0.56) | ACKR3CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428456-B2 | 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2016-08-30 | — | — | US | disclosed |
| US-20150336893-A1 | 1-[m-Carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide Derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336893-A1 | 1-[m-Carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide Derivatives | CXCR1, CXCR5, CXCR4 | ACKR3 9/4885CDK5 998/4885CDK5R1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.